ContraFect Corp logo

ContraFect Corp

OTCPK:CFRXQ (USA)  
$ 0.02 -0.00108 (-5.66%) 01:21 PM EST
At Loss
Market Cap:
$ 192.00K
Enterprise V:
$ -2.66M
Volume:
3.12K
Avg Vol (2M):
22.85K
Also Trade In:
Volume:
3.12K
At Loss
Avg Vol (2M):
22.85K

Business Description

Description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 2.12
Equity-to-Asset -0.63
Debt-to-Equity -0.44
Debt-to-EBITDA -0.09
Interest Coverage N/A
N/A
N/A
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 25.8
3-Year EPS without NRI Growth Rate 23.6
3-Year FCF Growth Rate 30.6

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 39.99
9-Day RSI 43.07
14-Day RSI 44.43
6-1 Month Momentum % -93.3
12-1 Month Momentum % -98.84

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.53
Quick Ratio 0.53
Cash Ratio 0.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -45.9
Shareholder Yield % -8294.72

Profitability Rank

Name Current Vs Industry Vs History
ROA % -130.28
ROIC % -560.14
ROC (Joel Greenblatt) % -1108.61

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT 0.09
EV-to-EBITDA 0.09
EV-to-FCF 0.07
Earnings Yield (Greenblatt) % 1111.11
FCF Yield % -18544.79

Financials (Next Earnings Date:2024-05-15 Est.)

CFRXQ's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:CFRXQ

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

ContraFect Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -19.27
Beta -0.86
Volatility % 96.66
14-Day RSI 44.43
14-Day ATR ($) 0.004171
20-Day SMA ($) 0.022116
12-1 Month Momentum % -98.84
52-Week Range ($) 0.0111 - 2.94
Shares Outstanding (Mil) 10.7

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ContraFect Corp Filings

Filing Date Document Date Form
No Filing Data

ContraFect Corp Stock Events

Financials Calendars
Event Date Price($)
No Event Data

ContraFect Corp Frequently Asked Questions

What is ContraFect Corp(CFRXQ)'s stock price today?
The current price of CFRXQ is $0.02. The 52 week high of CFRXQ is $2.94 and 52 week low is $0.01.
When is next earnings date of ContraFect Corp(CFRXQ)?
The next earnings date of ContraFect Corp(CFRXQ) is 2024-05-15 Est..
Does ContraFect Corp(CFRXQ) pay dividends? If so, how much?
ContraFect Corp(CFRXQ) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1